Glycation of α-synuclein amplifies the binding with glyceraldehyde-3-phosphate dehydrogenase.


Journal

International journal of biological macromolecules
ISSN: 1879-0003
Titre abrégé: Int J Biol Macromol
Pays: Netherlands
ID NLM: 7909578

Informations de publication

Date de publication:
15 Apr 2019
Historique:
received: 18 11 2018
revised: 14 01 2019
accepted: 14 01 2019
pubmed: 19 1 2019
medline: 20 6 2019
entrez: 19 1 2019
Statut: ppublish

Résumé

α-Synuclein was recently found to interact with moonlighting glycolytic enzyme glyceraldehyde-3-phosphate dehydrogenase (GAPDH) involved in neurodegenerative diseases development. In the present work, we have analyzed influence of α-synuclein glycation on this interaction, because the literature data suggest relation between diabetes and Parkinson's disease. According to zeta potential measurement, glycation can shift the charge of α-synuclein to more negative values that was pronounced in case of modification by glyceraldehyde-3-phosphate. We selected carboxymethyl lysine as a typical advanced glycation end product and performed molecular dynamics simulations. The binding was found to be electrostatically driven and was significantly amplified after α-synuclein glycation because of increase the number of acidic residues. Since the main binding site was located in the anion-binding groove, which comprises the active site of GAPDH, enhanced binding of α-synuclein can result in GAPDH inactivation. This hypothesis was proven experimentally. Glycation of α-synuclein resulted in increase of GAPDH inactivation, and this effect was more pronounced in case of modification by glyceraldehyde-3-phosphate. The obtained results can reflect the probable relations between protein glycation and neurodegenerative diseases.

Identifiants

pubmed: 30658140
pii: S0141-8130(18)36292-5
doi: 10.1016/j.ijbiomac.2019.01.064
pii:
doi:

Substances chimiques

Glycation End Products, Advanced 0
SNCA protein, human 0
alpha-Synuclein 0
Glyceraldehyde 3-Phosphate 142-10-9
Glyceraldehyde-3-Phosphate Dehydrogenases EC 1.2.1.-

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

278-285

Informations de copyright

Copyright © 2019 Elsevier B.V. All rights reserved.

Auteurs

Pavel Semenyuk (P)

Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, Moscow, Russia. Electronic address: psemenyuk@belozersky.msu.ru.

Kseniya Barinova (K)

Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, Moscow, Russia.

Vladimir Muronetz (V)

Belozersky Institute of Physico-Chemical Biology, Lomonosov Moscow State University, Moscow, Russia; Faculty of Bioengineering and Bioinformatics, Lomonosov Moscow State University, Moscow, Russia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH